Advancing Gene Therapy By Solving Challenges In Scale-Up & Manufacturing

As the biopharmaceutical industry sharpens its focus on gene therapy, opportunities for advancements and challenges in manufacturing processes still remain. While the industry has

made progress to effectively treat and control diseases based on regulatory approvals for novel therapies, the industry needs to continue to find efficiencies and optimize manufacturing processes in order to deploy gene therapies economically and at scale.

In this Q&A, Dr. Ger Brophy, executive vice president of biopharma production at Avantor, offers insights on how the biopharma industry can evolve its processes through lessons learned from manufacturing monoclonal antibodies (mAbs) or vaccines, improving supplier collaboration, and other factors.